Cargando…
Influencing factors on the NMP-22 urine assay: an experimental model
BACKGROUND: The commercial NMP-22 urine assays for bladder cancer (BCa) detect nuclear mitotic apparatus protein 1 (NUMA1) using monoclonal antibodies. It remains unclear whether these assays are monitoring a tumor antigen or some other phenomenon associated with the disease state. In this study, we...
Autores principales: | Miyake, Makito, Goodison, Steve, Giacoia, Evan Gomes, Rizwani, Wasia, Ross, Shanti, Rosser, Charles J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480828/ https://www.ncbi.nlm.nih.gov/pubmed/22928931 http://dx.doi.org/10.1186/1471-2490-12-23 |
Ejemplares similares
-
Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature
por: Zhang, Ge, et al.
Publicado: (2014) -
Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers
por: Miyake, Makito, et al.
Publicado: (2013) -
Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions
por: Miyake, Makito, et al.
Publicado: (2013) -
Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection
por: Miyake, Makito, et al.
Publicado: (2013) -
Simultaneous multi-analyte urinary protein assay for bladder cancer detection
por: Rosser, Charles J, et al.
Publicado: (2014)